CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.
Servier and Transgene have signed a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies.
NICE's Cancer Drugs Fund (CDF) is driving early access to new drugs for lung cancer and sarcoma for NHS patients in England.
Healthcare and life science firm Arix Bioscience has acquired a stake in Mitoconix Bio as part of an oversubscribed $20m Series A financing round.
Repare Therapeutics has secured $68m in a Series A financing round which it will use to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers.
Rubius Therapeutics, which is developing red-cell therapeutics (RCTs) as a new class of medicines to address a range of indications, has raised $120m in a highly oversubscribed private financing.
eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
BiondVax Pharmaceuticals, which is developing a universal vaccine for all strains of influenza, has signed an agreement with the European Investment Bank (EIB) for a €20m loan.
Basilea Pharmaceutica International has signed a license agreement with Pfizer for its marketed antifungal Cresemba (isavuconazole) to treat life-threatening invasive mold infections.
Accenture and 1QBit have partnered with Biogen to develop a quantum-enabled molecular comparison application that could considerably improve advanced molecular design to accelerate drug discovery for complex neurological conditions like multiple sclerosis, Alzheimer’s, Lou Gehrig’s Disease and Parkinson’s.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.